top of page
Aug 3, 2026
The B-SILENT international study in France and Canada is designed to generate essential safety and performance data to support a future CE Mark submission.
LAKE FOREST, Calif., Aug. 3, 2026 /PRNewswire/ -- Sonorous Neurovascular, a pioneering medical device company focused on innovative solutions for cerebral venous diseases and neurovascular interventions, today announced a significant clinical milestone: the first patient enrollment in Canada under its international B-SILENT study (NCT07070089). The enrollment took place at The Ottawa Hospital under principal investigator Dr. Robert Fahed, marking an exciting step forward for the study's global expansion. Read More
bottom of page